PRESS RELEASE
News
-
-
-
PRESS RELEASE
Zentiva announces voluntary public purchase offer for APONTIS PHARMA – Investment Agreement signed
Zentiva announces voluntary public purchase offer for APONTIS PHARMA with a 52.9% premium over the closing share price on 15 October 2024. Zentiva to acquire approx. 37.5% stake through share sale and purchase agreement with main shareholder -
PRESS RELEASE
APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer
APONTIS PHARMA partners with Zentiva for growth, offering shareholders EUR 10.00 per share in a voluntary public purchase offer. Zentiva aims for majority stake and strategic collaboration -
PRESS RELEASE
EQS-Adhoc: APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer
APONTIS PHARMA and Zentiva enter into investment agreement for voluntary public purchase offer at EUR 10.00 per share in cash. Zentiva aims to support future growth of APONTIS PHARMA -
-
-
PRESS RELEASE
SNP: Significant Increase of Revenue and Earnings in the Third Quarter – Further Raise of Full-Year Guidance 2024
SNP reports significant increase in revenue and earnings for Q3 2024, raises full-year guidance. Order entry up 24% to €75 million, revenue up 24% to €67 million, EBIT margin at 12% -
-
